Halozyme COO Departs, Stock Down 3.1%

Executive Departure

Halozyme Therapeutics Inc. (NASDAQ:HALO) filed a Form 8‑K announcing that its Senior Vice President and Chief Operating Officer, Cortney Caudill, will leave the company effective June 30, 2026. The filing expressed gratitude for Caudill’s contributions during her tenure but did not disclose the reasons for her departure nor any plan for a successor.

Market Reaction

Following the 8‑K disclosure, Halozyme’s shares declined 3.1 % in after‑hours trading on Thursday, reflecting investor response to the leadership change.

Additional Information

No further details regarding a replacement for the COO role were provided in the filing.